Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin agents in anxiety.

D P Taylor1

  • 1Pharmaceutical Research and Development Division, Bristol-Myers Company, Wallingford, Connecticut 06492.

Annals of the New York Academy of Sciences
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translating Dental, Oral, and Craniofacial Regenerative Medicine Innovations to the Clinic through Interdisciplinary Commercial Translation Architecture.

Journal of dental research·2021
Same author

Long-term control of olfactory neuroblastoma in a dog treated with surgery and radiation therapy.

Australian veterinary journal·2017
Same author

Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas.

Australian veterinary journal·2017
Same author

Piroxicam and doxycycline treatment for an oral squamous cell carcinoma in an inshore bottlenose dolphin (Tursiops aduncus).

Australian veterinary journal·2016
Same author

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system.

British journal of cancer·2014
Same author

Sexual Attraction and Mating Patterns in Cylindrocorpus longistoma and C. curzii (Nematoda: Cylindrocorporidae).

Journal of nematology·2009
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

Benzodiazepine side effects spurred the search for new anxiety drugs, leading to buspirone and a focus on serotonin. New serotonergic agents are now in development, advancing anxiety treatment and understanding.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Benzodiazepine anxiolytics have significant side effects, necessitating the development of safer alternatives.
  • Buspirone emerged as a novel anxiolytic, highlighting the role of serotonin in anxiety pharmacotherapy.

Purpose of the Study:

  • To review the development of novel anxiolytic agents.
  • To explore the role of serotonergic agents in anxiety treatment.
  • To discuss the impact of these developments on understanding anxiety's neurobiology.

Main Methods:

  • Review of preclinical and clinical investigations into novel anxiolytic agents.
  • Analysis of the pharmacological mechanisms of emerging serotonergic drugs.
  • Examination of the implications for animal models and understanding anxiety.

Related Experiment Videos

Main Results:

  • Buspirone represents a significant advancement, with serotonin identified as a key target.
  • Several classes of serotonergic agents (5-HT1A partial agonists, 5-HT2 antagonists, 5-HT3 antagonists) are under development.
  • These advancements are expected to refine animal models and deepen the understanding of anxiety.

Conclusions:

  • The development of novel serotonergic anxiolytics offers improved treatment options.
  • These agents will enhance the understanding of anxiety's neurobiological basis.
  • Further research with these agents promises insights into other disorders and drug mechanisms.